Albireo Pharma (ALBO) Misses Q1 EPS by 7c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Albireo Reports First Quarter 2019 Financial Results
May 9, 2019 7:30 AM EDTOdevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as plannedInitiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announcedOdevixibat pivotal trial in biliary atresia on track to begin H2 2019IND cleared to initiate elobixibat Phase 2 trial in NASH Q2 2019Management to host conference call and webcast today at 10 a.m. EDT
BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the first quarter... More
